Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, ...

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...

The pretreatment evaluation of patient-reported, health-related quality of life provides valuable prognostic information on ...

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong ...

Researchers sought to determine whether adding selinexor to chemotherapeutic induction and consolidation regimen would improve outcomes in AML.

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed ...

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...

Naval Daver, MD, who leads a number of acute myeloid leukemia (AML) research trials at MD Anderson Cancer Center in Houston, looks forward to a future where the treatment for AML is truly personalized ...

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, ...

Neighborhood disinvestment, characterized by infrastructure deterioration, is linked to increased stress and adverse cancer outcomes, necessitating further research. Racial disparities in acute ...

The study, titled “Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” was recently published in Blood and focuses on acute myeloid ...